Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
This study is being done to see if adding the study drug, cemiplimab, to the standard therapy with dabrafenib and trametinib is an effective treatment against anaplastic thyroid cancer.
Anaplastic Thyroid Cancer|Thyroid Cancer|BRAF Gene Mutation|BRAF Mutation-Related Tumors
DRUG: Dabrafenib|DRUG: Trametinib
Overall Response Rate per RECIST 1.1 Criteria, Response and progression will be evaluated by using criteria proposed in RECIST 1.1., 2 years
This study is being done to see if adding the study drug, cemiplimab, to the standard therapy with dabrafenib and trametinib is an effective treatment against anaplastic thyroid cancer.